The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid, and Gentamicin
REL-1017 (esmethadone) is a novel N-methyl-D-aspartate receptor (NMDAR) antagonist and promising rapid antidepressant candidate. Using fluorometric imaging plate reader (FLIPR) assays, we studied the effects of quinolinic acid (QA) and gentamicin, with or without L-glutamate and REL-1017, on intrace...
Saved in:
Main Authors: | Ezio Bettini (Author), Sara De Martin (Author), Andrea Mattarei (Author), Marco Pappagallo (Author), Stephen M. Stahl (Author), Francesco Bifari (Author), Charles E. Inturrisi (Author), Franco Folli (Author), Sergio Traversa (Author), Paolo L. Manfredi (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
by: Ezio Bettini, et al.
Published: (2022) -
REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats
by: Francesco Bifari, et al.
Published: (2022) -
REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study
by: Sara De Martin, et al.
Published: (2021) -
Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
by: Nicola Ferri, et al.
Published: (2023) -
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment
by: Nicola Ferri, et al.
Published: (2024)